GlassScriptPhysician profile
Cathy A Macknet
NPI 1639104391
$6,627.40
in general payments reported to CMS, 2019-2025
29 companies · $856 in 2025
The $856 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $802 · 2021: $486 · 2022: $1,053 · 2023: $1,302 · 2024: $892 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,965 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.07 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,397.65 | 2020-2025 | |
| Janssen Biotech, INC. | $923.86 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $669.39 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $549.83 | 2020-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $534.48 | 2019-2025 | |
| Ucb, INC. | $464.77 | 2022-2025 | Bimzelx, Cimzia |
| Biofrontera INC. | $440.38 | 2019 | |
| Pfizer INC. | $356.37 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $268.98 | 2020-2022 | |
| Genentech USA, INC. | $241.25 | 2019-2022 | |
| Lilly USA, LLC | $105.65 | 2020-2025 | Ebglyss |
| Sun Pharmaceutical Industries INC. | $80.82 | 2019-2025 | |
| Leo Pharma INC. | $80.09 | 2022-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.85 | 2023-2024 | Spevigo, Cyltezo |
| Incyte Corporation | $59.97 | 2022-2024 | Opzelura |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $48.38 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $47.14 | 2020-2021 | |
| Galderma Laboratories, L.P. | $41.56 | 2025 | Nemluvio |
| Paratek Pharmaceuticals, INC. | $37.61 | 2023 | Nuzyra |
| Arcutis Biotherapeutics, INC. | $37.56 | 2024-2025 | Zoryve |
| Amgen INC. | $32.73 | 2024 | Otezla |
| Organon LLC | $28.45 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $25.49 | 2020 | |
| Glaxosmithkline, LLC. | $19.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.20 | 2025 | Sotyktu |
| Tactile Systems Technology INC | $16.61 | 2020 | |
| Medtronic, INC. | $14.53 | 2025 | Venaseal |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.77 | 2019 | |
| Strata Skin Sciences, INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Macknet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.